Discontinued — last reported Q4 '25
Cigna D&A decreased by 10.0% to $650.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.6%, from $674.00M to $650.00M. Over 4 years (FY 2021 to FY 2025), D&A shows relatively stable performance with a -1.3% CAGR.
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
depreciation_and_amortization_cf| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $731.00M | $734.00M | $743.00M | $717.00M | $759.00M | $726.00M | $735.00M | $749.00M | $755.00M | $766.00M | $765.00M | $741.00M | $738.00M | $650.00M | $646.00M | $674.00M | $682.00M | $697.00M | $722.00M | $650.00M |
| QoQ Change | — | +0.4% | +1.2% | -3.5% | +5.9% | -4.3% | +1.2% | +1.9% | +0.8% | +1.5% | -0.1% | -3.1% | -0.4% | -11.9% | -0.6% | +4.3% | +1.2% | +2.2% | +3.6% | -10.0% |
| YoY Change | — | — | — | — | +3.8% | -1.1% | -1.1% | +4.5% | -0.5% | +5.5% | +4.1% | -1.1% | -2.3% | -15.1% | -15.6% | -9.0% | -7.6% | +7.2% | +11.8% | -3.6% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Cigna Healthcare | $113.00M | $97.00M | $83.00M | $83.00M | $81.00M | $88.00M | $87.00M | $83.00M |
| Other Operations | $2.00M | $4.00M | — | $2.00M | $9.00M | $2.00M | $3.00M | $2.00M |
| Total | $738.00M | $650.00M | $646.00M | $674.00M | $682.00M | $697.00M | $722.00M | $650.00M |